<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414050</url>
  </required_header>
  <id_info>
    <org_study_id>V232-057</org_study_id>
    <secondary_id>2006_053</secondary_id>
    <secondary_id>2006-001638-42</secondary_id>
    <nct_id>NCT00414050</nct_id>
  </id_info>
  <brief_title>A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)</brief_title>
  <official_title>A Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted in healthy infants and will provide new immunogenicity and safety
      data for the modified process hepatitis B vaccine. This study was conducted to address the
      following: to evaluate the immunogenicity and safety data of the 5 microgram dose of the
      modified process hepatitis B vaccine compared with a 10 microgram dose of the modified
      process hepatitis B vaccine, to evaluate another dosing schedule of 2, 4, and 6 months, and
      to provide descriptive immunogenicity data of another marketed vaccine (ENGERIX-B®).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2006</start_date>
  <completion_date type="Actual">October 24, 2007</completion_date>
  <primary_completion_date type="Actual">October 22, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Seroresponders to the Modified Process Hepatitis B Vaccine (5 μg and 10 μg Dose), RECOMBIVAX HB™ Hepatitis B Vaccine (Currently Licensed Vaccine), and ENGERIX-B®</measure>
    <time_frame>7 months of age (1 month after 3 doses)</time_frame>
    <description>The percentage of participants as measured by Seroresponse. Seroresponse was defined as anti-hepatitis B surface antibodies greater than or equal to 10 milli-International Units (mIU)/mL. Success on the primary immunogenicity hypothesis required demonstrating an adequate anti-HBs seroprotection rate response for either modified process hepatitis B 5 μg vaccine or RECOMBIVAX HB™. Specifically, the lower bound of the multiplicity adjusted 95% confidence interval (CI) on the seroprotection rate for either vaccine was required to be above 90.0%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody to Hepatitis B Surface Antigen Geometric Mean Titer (Anti-HBs GMT) Responses for Modified Process Vaccine (5 μg and 10 μg), RECOMBIVAX™ Hepatitis B (Currently Licensed Vaccine), and ENGERIX-B®</measure>
    <time_frame>7 months of age (1 month after 3 doses)</time_frame>
    <description>Geometric Mean Titer - Antibody titer is a laboratory test that measures the presence and amount of antibodies in blood.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1718</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Modified Process Hepatitis B vaccine 5 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RECOMBIVAX HB™ Hepatitis B Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified Process Hepatitis B vaccine 10 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENGERIX-B®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Modified Process Hepatitis B Vaccine (Experimental)</intervention_name>
    <description>Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).</description>
    <arm_group_label>Modified Process Hepatitis B vaccine 5 μg</arm_group_label>
    <arm_group_label>Modified Process Hepatitis B vaccine 10 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B Vaccine (Recombinant)</intervention_name>
    <description>RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.</description>
    <arm_group_label>RECOMBIVAX HB™ Hepatitis B Vaccine</arm_group_label>
    <other_name>RECOMBIVAX HB™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B Vaccine (Recombinant)</intervention_name>
    <description>ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months</description>
    <arm_group_label>ENGERIX-B®</arm_group_label>
    <other_name>ENGERIX-B®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is a healthy infant approximately 2 months of age

        Exclusion Criteria:

          -  Birth mother is a known carrier of hepatitis B virus or another known carrier has
             lived in close contact with the participant

          -  Participant's birth mother did not receive any prenatal care

          -  Participant has previous history of hepatitis B infection

          -  Participant has been vaccinated against hepatitis B or birth mother was vaccinated
             within 6 months before birth of participant

          -  Participant has had a fever within 72 hours of study start

          -  Participant has received any blood-derived product or birth mother received
             blood-derived product within 6 months of birth of participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Finland</country>
    <country>Norway</country>
  </removed_countries>
  <results_reference>
    <citation>Vesikari T, Martin JC, Liss CL, Liska V, Schödel FP, Bhuyan PK. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. Pediatr Infect Dis J. 2011 Jul;30(7):e109-13. doi: 10.1097/INF.0b013e31821ed1a4.</citation>
    <PMID>21552183</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2006</study_first_posted>
  <results_first_submitted>October 15, 2008</results_first_submitted>
  <results_first_submitted_qc>March 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 14, 2009</results_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>15-Nov-2006 (First Participant Enrolled in Study) to 24-Oct-2007 (Last Participant had their Last Visit). Last participant completed follow-up: 16-Oct-2007.This study was conducted at 15 sites; 14 in Finland and 1 in Norway.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Modified Process Hepatitis B Vaccine 5 µg (Micrograms)</title>
          <description>Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="P2">
          <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
          <description>Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="P3">
          <title>Modified Process Hepatitis B Vaccine 10 µg</title>
          <description>Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="P4">
          <title>ENGERIX-B®</title>
          <description>Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="427"/>
                <participants group_id="P3" count="429"/>
                <participants group_id="P4" count="431"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="426"/>
                <participants group_id="P3" count="429"/>
                <participants group_id="P4" count="431"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="421"/>
                <participants group_id="P3" count="425"/>
                <participants group_id="P4" count="425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="424"/>
                <participants group_id="P2" count="419"/>
                <participants group_id="P3" count="425"/>
                <participants group_id="P4" count="424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="422"/>
                <participants group_id="P2" count="419"/>
                <participants group_id="P3" count="423"/>
                <participants group_id="P4" count="423"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject discontinued for other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modified Process Hepatitis B Vaccine 5 µg (Micrograms)</title>
          <description>Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="B2">
          <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
          <description>Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Modified Process Hepatitis B Vaccine 10 µg</title>
          <description>Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="B4">
          <title>ENGERIX-B®</title>
          <description>Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="431"/>
            <count group_id="B2" value="427"/>
            <count group_id="B3" value="429"/>
            <count group_id="B4" value="431"/>
            <count group_id="B5" value="1718"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="10.18"/>
                    <measurement group_id="B2" value="62.9" spread="10.15"/>
                    <measurement group_id="B3" value="63.3" spread="9.83"/>
                    <measurement group_id="B4" value="62.8" spread="9.81"/>
                    <measurement group_id="B5" value="63.1" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="208"/>
                    <measurement group_id="B4" value="201"/>
                    <measurement group_id="B5" value="816"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="221"/>
                    <measurement group_id="B4" value="230"/>
                    <measurement group_id="B5" value="902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Seroresponders to the Modified Process Hepatitis B Vaccine (5 μg and 10 μg Dose), RECOMBIVAX HB™ Hepatitis B Vaccine (Currently Licensed Vaccine), and ENGERIX-B®</title>
        <description>The percentage of participants as measured by Seroresponse. Seroresponse was defined as anti-hepatitis B surface antibodies greater than or equal to 10 milli-International Units (mIU)/mL. Success on the primary immunogenicity hypothesis required demonstrating an adequate anti-HBs seroprotection rate response for either modified process hepatitis B 5 μg vaccine or RECOMBIVAX HB™. Specifically, the lower bound of the multiplicity adjusted 95% confidence interval (CI) on the seroprotection rate for either vaccine was required to be above 90.0%.</description>
        <time_frame>7 months of age (1 month after 3 doses)</time_frame>
        <population>Participants who follow the protocol, do not have major protocol deviations and have post-vaccination serology within specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine 5 µg (Micrograms)</title>
            <description>Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
            <description>Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Modified Process Hepatitis B Vaccine 10 µg</title>
            <description>Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>ENGERIX-B®</title>
            <description>Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Seroresponders to the Modified Process Hepatitis B Vaccine (5 μg and 10 μg Dose), RECOMBIVAX HB™ Hepatitis B Vaccine (Currently Licensed Vaccine), and ENGERIX-B®</title>
          <description>The percentage of participants as measured by Seroresponse. Seroresponse was defined as anti-hepatitis B surface antibodies greater than or equal to 10 milli-International Units (mIU)/mL. Success on the primary immunogenicity hypothesis required demonstrating an adequate anti-HBs seroprotection rate response for either modified process hepatitis B 5 μg vaccine or RECOMBIVAX HB™. Specifically, the lower bound of the multiplicity adjusted 95% confidence interval (CI) on the seroprotection rate for either vaccine was required to be above 90.0%.</description>
          <population>Participants who follow the protocol, do not have major protocol deviations and have post-vaccination serology within specified day ranges.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="398"/>
                <count group_id="O4" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="98.3" upper_limit="100"/>
                    <measurement group_id="O2" value="98.5" lower_limit="97.2" upper_limit="99.8"/>
                    <measurement group_id="O3" value="100" lower_limit="99.9" upper_limit="100"/>
                    <measurement group_id="O4" value="99.5" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody to Hepatitis B Surface Antigen Geometric Mean Titer (Anti-HBs GMT) Responses for Modified Process Vaccine (5 μg and 10 μg), RECOMBIVAX™ Hepatitis B (Currently Licensed Vaccine), and ENGERIX-B®</title>
        <description>Geometric Mean Titer - Antibody titer is a laboratory test that measures the presence and amount of antibodies in blood.</description>
        <time_frame>7 months of age (1 month after 3 doses)</time_frame>
        <population>Participants who follow the protocol, do not have major protocol deviations and have post-vaccination serology within specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine 5 µg (Micrograms)</title>
            <description>Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O2">
            <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
            <description>Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Modified Process Hepatitis B Vaccine 10 µg</title>
            <description>Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
          </group>
          <group group_id="O4">
            <title>ENGERIX-B®</title>
            <description>Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody to Hepatitis B Surface Antigen Geometric Mean Titer (Anti-HBs GMT) Responses for Modified Process Vaccine (5 μg and 10 μg), RECOMBIVAX™ Hepatitis B (Currently Licensed Vaccine), and ENGERIX-B®</title>
          <description>Geometric Mean Titer - Antibody titer is a laboratory test that measures the presence and amount of antibodies in blood.</description>
          <population>Participants who follow the protocol, do not have major protocol deviations and have post-vaccination serology within specified day ranges.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="398"/>
                <count group_id="O4" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="748.2" lower_limit="672.0" upper_limit="833.1"/>
                    <measurement group_id="O2" value="376.8" lower_limit="331.4" upper_limit="428.5"/>
                    <measurement group_id="O3" value="981.5" lower_limit="891.0" upper_limit="1081.2"/>
                    <measurement group_id="O4" value="556.6" lower_limit="491.8" upper_limit="629.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Induced (effected) Geometric Mean Titer for the Modified Hepatitis B Process Vaccine and RECOMBIVAX Hepatitis B vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Modified Process Hepatitis B vaccine-5µg (micrograms) declared non-inferior to RECOMBIVAX HB™ if the lower bound of the 95% Confidence Interval for the ratio of Geometric Mean Titers (Modified Process Vaccine 5 micrograms/RECOMBIVAX HB™) was &gt;= 0.67. The study had 98 percent power for this test, based on an assumption of true equality.</non_inferiority_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs): up to 5 months (entire study period); Systemic non-serious adverse events (NSAEs): up to 14 days after any vaccination; Injection-site NSAEs: up to 5 days after any vaccination</time_frame>
      <desc>All randomized participants with follow-up who received at least one dose of study vaccine. Below tables exclude one RECOMBIVAX HB participant who received 2 doses of RECOMBIVAX HB™ and 1 dose of modified process hepatitis B vaccine 10 μg, and one ENGERIX-B® participant who received 2 doses of ENGERIX-B® and 1 dose of RECOMBIVAX HB™.</desc>
      <group_list>
        <group group_id="E1">
          <title>Modified Process Hepatitis B Vaccine 5 µg (Micrograms)</title>
          <description>Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="E2">
          <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
          <description>Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="E3">
          <title>Modified Process Hepatitis B Vaccine 10 µg</title>
          <description>Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="E4">
          <title>ENGERIX-B®</title>
          <description>Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="429"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nutritional condition abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="429"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="294" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="276" subjects_at_risk="429"/>
                <counts group_id="E4" subjects_affected="288" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="430"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="424"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="429"/>
                <counts group_id="E4" events="23" subjects_affected="22" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="430"/>
                <counts group_id="E2" events="36" subjects_affected="26" subjects_at_risk="424"/>
                <counts group_id="E3" events="31" subjects_affected="26" subjects_at_risk="429"/>
                <counts group_id="E4" events="26" subjects_affected="18" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="169" subjects_affected="114" subjects_at_risk="430"/>
                <counts group_id="E2" events="157" subjects_affected="109" subjects_at_risk="424"/>
                <counts group_id="E3" events="138" subjects_affected="91" subjects_at_risk="429"/>
                <counts group_id="E4" events="139" subjects_affected="107" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="78" subjects_affected="62" subjects_at_risk="430"/>
                <counts group_id="E2" events="65" subjects_affected="57" subjects_at_risk="424"/>
                <counts group_id="E3" events="68" subjects_affected="56" subjects_at_risk="429"/>
                <counts group_id="E4" events="65" subjects_affected="53" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="169" subjects_affected="128" subjects_at_risk="430"/>
                <counts group_id="E2" events="160" subjects_affected="117" subjects_at_risk="424"/>
                <counts group_id="E3" events="153" subjects_affected="116" subjects_at_risk="429"/>
                <counts group_id="E4" events="124" subjects_affected="94" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="117" subjects_affected="79" subjects_at_risk="430"/>
                <counts group_id="E2" events="96" subjects_affected="73" subjects_at_risk="424"/>
                <counts group_id="E3" events="90" subjects_affected="60" subjects_at_risk="429"/>
                <counts group_id="E4" events="92" subjects_affected="66" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection-site induration</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="430"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="424"/>
                <counts group_id="E3" events="26" subjects_affected="24" subjects_at_risk="429"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="109" subjects_affected="78" subjects_at_risk="430"/>
                <counts group_id="E2" events="111" subjects_affected="85" subjects_at_risk="424"/>
                <counts group_id="E3" events="110" subjects_affected="87" subjects_at_risk="429"/>
                <counts group_id="E4" events="98" subjects_affected="65" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="430"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="424"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="429"/>
                <counts group_id="E4" events="25" subjects_affected="23" subjects_at_risk="428"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="57" subjects_affected="53" subjects_at_risk="430"/>
                <counts group_id="E2" events="54" subjects_affected="47" subjects_at_risk="424"/>
                <counts group_id="E3" events="68" subjects_affected="59" subjects_at_risk="429"/>
                <counts group_id="E4" events="57" subjects_affected="51" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="51" subjects_affected="41" subjects_at_risk="430"/>
                <counts group_id="E2" events="49" subjects_affected="39" subjects_at_risk="424"/>
                <counts group_id="E3" events="48" subjects_affected="39" subjects_at_risk="429"/>
                <counts group_id="E4" events="48" subjects_affected="41" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="430"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="424"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="429"/>
                <counts group_id="E4" events="26" subjects_affected="25" subjects_at_risk="428"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1 800 672 6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

